METHODS

Related by string. methods * * harsh interrogation methods . methods Debit Card . Safety Reliability Methods . interrogation methods . contraceptive methods . brainwash methods . coercive interrogation methods . computational methods . Humane Methods . unorthodox methods . coercive methods . journal Nature Methods . If probabilistic methods . Air Methods . Nature Methods *

Related by context. All words. (Click for frequent words.) 67 METHOD 63 Methods 60 retrospective cohort 60 MATERIALS AND METHODS 59 RENAL 59 dimensional echocardiography 59 retrospective cohort study 59 Prospective Randomized Trial 58 retrospectively analyzed 58 retrospective observational study 58 DIAGNOSTIC 58 observational cohort study 58 prospective nonrandomized 57 randomized multicenter trial 57 CAUTIONS 57 retrospectively reviewed 57 Randomized Controlled Trial 57 Intervention Trial 57 Randomized Evaluation 56 Patency 56 histologically confirmed 56 multicenter prospective 56 prospective observational 56 histologically proven 56 male Wistar rats 56 underwent surgical resection 56 underwent CABG 56 prospectively randomized 55 OBJECTIVES 55 logistic regression analysis 55 multicentre randomized 55 semiquantitative 55 Multicenter 55 Randomized Clinical Trial 55 Main Outcome Measures 55 longitudinal cohort study 55 multicenter randomized controlled 55 underwent resection 55 THIS STUDY 54 prospective multicenter study 54 Prospective Multicenter 54 duplex ultrasonography 54 multicentre prospective 54 Meta Analysis 54 prospectively enrolled 54 prospective multicenter 54 Raloxifene Evaluation MORE 54 randomized multicenter 54 Randomized Controlled Trials 54 Sprague Dawley rats 54 Coronary Angiography 54 ILLUSTRATE 54 Echocardiographic 54 pT2 54 Ultrasonography 54 DEFER 54 COPERNICUS 53 Subtypes 53 CONFIRM 53 clinicopathologic 53 CONCLUSIONS 53 Carotid Revascularization Endarterectomy vs. 53 male Sprague Dawley 53 Infarct 53 REGARDS 53 total knee arthroplasties 53 Relapsing Remitting Multiple Sclerosis 53 EURIDIS 53 ultrasonographic 53 immunohistochemical staining 53 substudy 53 Randomized Controlled 53 TRANSFORMS 53 n = 53 Prospective Randomized 53 fluorodeoxyglucose positron emission tomography 53 Histological 53 total hip arthroplasties 53 multicenter randomized 53 prospective cohort 53 multiple logistic regression 53 underwent radical prostatectomy 53 TAXUS ATLAS 53 Cardiac Allograft Rejection 53 CAMMS# 53 logistic regression model 53 undetectable HBV DNA 53 Conclusions 53 ANOVA 53 Histologic 53 Kaplan Meier analysis 53 Lesion 53 transcranial Doppler 53 NSABP B 53 Genotypes 53 Angiographic 53 multicenter randomized placebo controlled 53 overnight polysomnography 52 transvaginal sonography 52 MR Angiography 52 TRUS 52 TAXUS ARRIVE 52 Ischemic Stroke 52 PROCEDURE 52 biopsy specimens 52 RE LY ® 52 Stent Restenosis 52 prospective multicentre 52 Controlled Trial 52 Comorbidities 52 transthoracic 52 Treatment Outcome 52 logistic regression analyzes 52 chest radiographs 52 Infarction 52 dosing cohorts 52 transrectal ultrasound guided 52 prostate cancer PCa 52 Clinical Relevance 52 multivariate analyzes 52 multicenter multinational 52 immunocompetent 52 Outcomes Study 52 Placebo Controlled Trial 52 STRATEGY FOR AN OPEN 52 II Clinical Trial 52 TREATMENT 52 BACKGROUND AND 52 Patients Undergoing 52 randomized blinded 52 gadolinium enhanced 52 echo planar 52 phase IIIb 52 Histopathological 52 multicentre 52 SYNTAX 52 transabdominal 52 arthroplasties 52 Transurethral 52 Evaluable 52 Western blotting 51 Myocardial Ischemia 51 Sonographic 51 LRTI 51 Vertebral Fracture 51 Thrombolysis 51 Kids Inpatient Database 51 immunostaining 51 Urogenital Distress Inventory 51 Chemoradiation 51 nondiabetic patients 51 core needle biopsies 51 longitudinal observational study 51 Depressive Symptoms 51 Systematic Review 51 prospective randomized multicenter 51 prospective randomized controlled 51 FDG-PET/CT 51 Main Outcome Measure 51 RADIANT 51 ANCOVA 51 NSTE ACS 51 % CI #.#-#.# [003] 51 DETECTION 51 Brief Psychiatric 51 Doppler echocardiography 51 Acute Myocardial Infarction 51 REYATAZ r arm 51 hepatic resection 51 Stent Implantation 51 Carotid Stenting 51 echocardiographic 51 HRCT 51 Cardiopulmonary bypass 51 CT Angiography 51 Coronary Artery Bypass Graft 51 evaluable 51 binary logistic regression 51 mean ± SEM 51 Systemic Sclerosis 51 sonographic 51 prospective observational cohort 51 ± SD 51 undergone radical prostatectomy 51 NMIBC 51 euthyroid 51 Dual Antiplatelet Therapy 51 PROVE IT 51 biochemical relapse 51 nonmetastatic 51 Non Responders 51 Univariate 51 Sustained Efficacy 51 #mg QD [002] 51 SF #v# 51 undergoing radical cystectomy 51 specific antigen PSA 51 Malformations 51 ug dose 51 TRUST AND 51 ASST 51 dimensional ultrasonography 51 Bare Metal Stents 51 Tumor Response 50 Incontinence Impact Questionnaire 50 subanalysis 50 logistic regression 50 histopathologic 50 Suicidality 50 prospective multicenter randomized 50 FINDINGS 50 CAVEATS 50 suicide attempters 50 nulliparous women 50 seronegative 50 REALISM 50 VIOLATIONS OF 50 surgically resected 50 Pearson correlation coefficient 50 Longitudinal 50 ± SEM 50 Carotid Endarterectomy 50 Hemodialysis Patients 50 randomized controlled trials RCTs 50 Carotid 50 REALITY Trial 50 PRoFESS 50 immunohistochemical analysis 50 prospectively evaluated 50 SCANS 50 Postoperative 50 Kruskal Wallis test 50 LHRH receptor positive 50 Acute Decompensated Heart Failure 50 Wistar rats 50 NOT GETTING 50 SPIRIT FIRST 50 TREATMENT FOR 50 HEART FAILURE 50 Catheter Ablation 50 Cardiogenic Shock 50 IN PATIENTS WITH 50 HCV SPRINT 50 lymphadenectomy 50 Randomized Study 50 multicenter randomized double 50 transcranial Doppler ultrasound 50 AUDIT 50 Radiofrequency Ablation 50 #F FDG PET 50 prospective longitudinal 50 ExTRACT TIMI 50 Metastatic Prostate Cancer 50 NHANES III 50 descending thoracic 50 Patients Receiving 50 Pooled Analysis 50 F FDG PET 50 Digital Mammographic Imaging 50 SERENE 50 renal tumors 50 DELIBERATIONS 50 leiomyomas 50 evaluable subjects 50 OBJECTIVE 50 Newly Diagnosed Multiple Myeloma 50 multicentre randomized double 50 TKAs 50 cervical lymph nodes 50 TEST RESULTS 50 prospective randomized 50 ST Segment Elevation 50 unfractionated heparin UFH 50 Epoetin Alfa 50 multivariable analysis 50 ACCOMPLISH 50 Rating Scale MADRS 49 BOLDER II 49 Autograft 49 CUSTOM II 49 RAMP UP 49 Randomized controlled 49 histologically 49 PREVAIL 49 ECG gated 49 Castration Resistant Prostate Cancer 49 Left Ventricular 49 J Clin Oncol 49 transrectal ultrasound 49 SUPPORT STAFF 49 Reperfusion 49 Solid Tumors 49 antral 49 Acute Physiology 49 Randomised 49 pathologic diagnosis 49 multicenter randomized clinical 49 subscale scores 49 multivariable logistic regression 49 Intervention Effectiveness CATIE 49 radical cystectomy 49 hemodynamically significant 49 MOCK 49 restenotic lesions 49 polysomnography PSG 49 Inflammatory Pain 49 Cardiovascular Events 49 plain radiographs 49 psychometric properties 49 Duodenal 49 perioperative complications 49 Risk Stratification 49 renal artery stenosis 49 laparoscopic cholecystectomy 49 serum samples 49 CARDIA 49 Correlates 49 Improves Outcomes 49 angiographically 49 esophageal carcinoma 49 underwent liver transplantation 49 Solid Tumours 49 Preoperatively 49 Data Extraction 49 T2DM 49 VNTR 49 MADRS score 49 primary percutaneous coronary 49 Acute Coronary 49 ASSISTED SUICIDE 49 ALLEGRO 49 Framingham Offspring 49 Localized Prostate Cancer 49 multicentric 49 Edge STudy 49 recurrent glioblastoma multiforme 49 abnormal cytology 49 odds ratios ORs 49 Proves Effective 49 peripheral blood mononuclear 49 multicentre study 49 histologic findings 49 Radiographic 49 TAPAS 49 transurethral resection 49 Asymptomatic 49 interobserver 49 Randomized Trials 49 HBeAg positive 49 varicoceles 49 Vertebroplasty 49 Methods Retrospective 49 Subset 49 #F FDG PET CT 49 Myocardial Infarction 49 histopathologic examination 49 multivariable Cox 49 Elderly Patients 49 meta regression 49 efficacy evaluable 49 Orthostatic Hypotension 49 BEHAVIORAL 49 Controlled Study 49 Predictive Value 49 liver biopsies 49 Chronic HCV 49 CORE OM 49 singleton pregnancies 49 digital subtraction angiography 49 interrater reliability 49 differentially expressed genes 49 Relapsing Multiple Sclerosis 49 DEFINED 49 Stable Angina 49 Radical Prostatectomy 49 Adjuvant Chemotherapy 49 FDG PET CT 49 Patient Populations 49 Percutaneous Coronary Intervention 49 Clinical Outcome 49 Generalized Anxiety Disorder 49 calcaneal fractures 49 chest radiograph 49 NCT# ClinicalTrials.gov 49 trials RCTs 49 Renal Artery 49 VARY 49 Efficacy Study 49 urolithiasis 49 X RAYS 49 renal biopsy 49 Randomized Double Blind 49 liver resection 49 Radiation Therapy Oncology 49 Functional Outcomes 49 Kidaro LynuxWorks ManageIQ Managed 49 Surgical Procedures 49 MR spectroscopy 49 APPROXIMATE 49 sonographic findings 48 Bone Mineral Density 48 Treatment Naive 48 Lower Limb 48 undergoing coronary angiography 48 HORIZONS 48 Baltimore Longitudinal Study 48 hemostatic efficacy 48 TYPES OF 48 BATTLING FOR 48 OBSERVED 48 Randomized Clinical Trials 48 breast carcinoma 48 TREATMENTS 48 percutaneous drainage 48 pharmacokinetic PK 48 Clinical Trial Evaluating 48 Chronic Heart Failure 48 prospectively 48 FDG PET scans 48 Multicenter Phase 48 liver transplant recipients 48 EQ 5D 48 preoperatively 48 antiretroviral naïve 48 nonrandomized 48 univariate 48 Multicenter Trial 48 nucleoside naive 48 karyotypes 48 computed tomographic 48 PEG IFN 48 AMISH 48 FASEB J. 48 TREATMENT OF 48 clinico pathological 48 bone scintigraphy 48 Univariate analysis 48 Patient Reported Outcome 48 OF LAW 48 Surgical Treatment 48 Sirolimus Eluting Stent 48 Progenitor Cells 48 posterolateral fusion 48 Transcranial Magnetic Stimulation 48 CLINICAL TRIAL 48 Prostatic 48 advanced neoplasia 48 Histopathologic 48 HYPERTENSION 48 Observational Study 48 Induction Therapy 48 intratympanic 48 Peripheral Arterial 48 OPERATIVE 48 STICH trial 48 Symptom Scale 48 FAIR TRIAL 48 Partial Onset Seizures 48 multicenter phase 48 Randomized 48 reflux esophagitis 48 CAUSES OF 48 Differential Diagnosis 48 Is Well Tolerated 48 semistructured interview 48 resected pancreatic cancer 48 Endovascular Repair 48 STICH 48 genotype 1a 48 TMC# C# 48 ovariectomized 48 CIMZIA TM certolizumab pegol 48 conducted retrospective cohort 48 UNDERSTANDING THE 48 Unstable Angina 48 RECIST Response Evaluation Criteria 48 distal radial fractures 48 MORTALITY 48 Partial Nephrectomy 48 GENES 48 EuroSCORE 48 retest reliability 48 Septic Shock 48 J Immunol 48 somatosensory evoked potentials 48 Liver biopsies 48 OMITTED 48 genes differentially expressed 48 PURPOSE 48 Treatment Naive HIV 48 bivariate analyzes 48 IMPLICATIONS 48 randomized crossover 48 operable breast cancer 48 Aortic Valve Replacement 48 multivariate logistic regression 48 ASSAYS 48 sonographic examinations 48 Long Term Outcomes 48 Abnormality 48 Immunosuppression 48 blinded randomized placebo controlled 48 Aortic Dissection 48 relapsing remitting MS RRMS 48 interquartile range IQR 48 relapsed MM 48 IQR 48 Comorbidity 48 NICE SUGAR 48 TUMORS 48 Resynchronization 48 CIN2 + 48 CHOOSE YOUR 48 #:#-# [031] 48 Percutaneous Coronary Interventions 48 prucalopride 48 SWOG 48 logistic regression models 48 postoperative radiographs 48 HALTS 48 PEDIATRIC 48 UNLOAD 48 D Dimer 48 TLUS 48 ECLS 48 fosbretabulin 48 HINTS 48 prespecified secondary 48 visceral metastases 48 Prognostic Significance 48 CT urography 48 pelvic lymph node dissection 48 Oral Fingolimod 48 posttreatment 48 Clostridium difficile Infection 48 Screening Trial DMIST 48 recanalization 48 OFF YOUR 48 -#.# ± [002] 48 DOWNWARD 48 Multicenter Study 48 Liver Failure 48 Acute Ischemic Stroke 48 euthymic patients 48 Ventricular Arrhythmias 48 Severe Asthma 48 Stenting 48 Screening Trial 48 Val HeFT 48 preoperative diagnosis 48 RELEVANCE 48 treatment naive genotype 48 acetabular fracture 48 Ventricular 48 GOUT 48 urothelial carcinoma 48 thyroidectomy 48 RECORD1 48 Uterine 48 multicenter Phase III 48 CHAMPION PCI 48 syndromal 48 multivariate Cox 48 HealthGrades analyzed 48 PRESERVE 48 paragangliomas 48 MALES 48 immunohistochemical 48 HEALTH PLAN 48 Antiviral Activity 48 intraobserver 48 psychiatric outpatients 48 anthropometric measurements 48 physiologic parameters 48 Partial Responses 47 Cardiovascular Outcomes 47 PATIENTS WHO 47 blind randomized controlled 47 Coronary Revascularization 47 OPCAB 47 elective percutaneous coronary 47 histological subtype 47 Thromboembolism 47 histopathological 47 patients evaluable 47 femora 47 label multicenter 47 ATTRACT 47 WASHED 47 Suicidal Ideation 47 Index CDAI 47 Ischemic 47 FDG PET imaging 47 Prostate Cancer Recurrence 47 Predict Risk 47 SEER registries 47 semistructured interviews 47 Prognostic Value 47 Prostatectomy 47 Figure 2C 47 MINDSET 47 NIH CPSI 47 microbiologically evaluable 47 clinicopathological 47 MDCT angiography 47 CT perfusion 47 MBq 47 Juvenile Idiopathic Arthritis 47 Statistically Significant 47 Allogeneic 47 intramedullary nailing 47 T1a 47 multicenter study 47 Atypical Hemolytic Uremic Syndrome 47 Transesophageal 47 remission CR 47 PHQ 9 47 TEST OF 47 Placebo controlled 47 Cytogenetic 47 stage IIIb IV 47 spirometric 47 Prostate Lung Colorectal 47 adrenalectomy 47 confidence intervals CIs 47 MR angiography 47 Polymorphism 47 achieved CCyR 47 Placebo Controlled Study 47 HGPIN 47 Abciximab 47 Total Knee Arthroplasty 47 extramedullary 47 Pathologic 47 interrater 47 Appears Safe 47 Health Questionnaire PHQ 47 Etiology 47 atrioventricular block 47 NHAMCS 47 C#BL 6 mice 47 Primary endpoints 47 DAS# scores 47 PCa 47 BLOOD TEST 47 polyposis 47 morphometric 47 Kidney Transplants 47 prepubertal 47 scintigraphy 47 patientswith 47 dose dose escalation 47 electrocardiographic 47 perfusion abnormalities 47 Coronary Artery Bypass Surgery 47 Decitabine 47 Outcome Measures 47 nephrectomy 47 dose escalation clinical 47 NEVO RES 47 resectable pancreatic cancer 47 TO AVOID PREGNANCY WHILE 47 Mitral Regurgitation 47 Predict Response 47 Grafts 47 Renal Cell Carcinoma 47 DEPENDENT 47 Leukocyte 47 Preoperative 47 SNHL 47 Regression Analysis 47 Health Assessment Questionnaire 47 prospectively defined 47 PsA 47 DLTs 47 Pain Rating Scale 47 Overactive Bladder 47 femoral neck fractures 47 elevated troponin 47 Current Beneficiary 47 Ectopic 47 VERDICT ON 47 Patients Treated With 47 Bonferroni correction 47 RECIST criteria 47 Inpatients 47 ABSTRACTS 47 papillary renal cell carcinoma 47 CALGB 47 multivariable analyzes 47 Multivariate analysis 47 univariate analysis 47 LVNC 47 radical nephrectomy 47 postintervention 47 dimensional sonography 47 radiographic findings 47 generalized estimating 47 Fracture Risk 47 NIHSS 47 peptic ulcer bleeding 47 serum leptin 47 Subgroup Analysis 47 linear regression analyzes 47 acetabular dysplasia 47 AND RECOMMENDATIONS 47 PIB PET 47 randomized clinical 47 Clinical Antipsychotic Trials 47 linear regressions 47 RVOT 47 unstable angina pectoris 47 BARACLUDE ® 47 intraperitoneal injection 47 pancreatic resection 47 REVISE 47 AIR CF1 47 ACS NSQIP 47 Patients Treated 47 Decompensated Heart Failure 47 Intravascular 47 DIFFER 47 Coronary CTA 47 DISPLAY OF 47 SYMPTOMS 47 Functional Assessment 47 imaging FMRI 47 Montgomery Åsberg Depression 47 POISE 47 prostate cancer CaP 47 postoperatively 47 Left Ventricular Dysfunction 47 XIENCE V demonstrated 47 cytologically confirmed 47 CAN NEVER 47 prostate carcinoma 47 Scintigraphy 47 NIS LL 47 MERIT ES 47 MESSAGE FROM 47 PROCEDURES 47 randomized controlled clinical 47 efavirenz EFV 47 Pivotal Trials 47 Pelvic Organ Prolapse 47 BUDGETING 47 Structured Clinical 47 pelvic lymphadenectomy 47 pelvic ultrasound 47 IMPOSSIBLE TO 47 conditional logistic regression 47 Acute Coronary Syndromes 47 Tumor Cell 47 Meta Analyses 47 null responder HCV 47 stage IIIB 47 J Virol 47 Neoplasms 47 partial remissions 47 Amniotic Fluid 47 Cystectomy 47 REVIVE Diabetes 47 Neonates 47 Ovarian PLCO Cancer 47 estimated glomerular filtration 47 TO RECOVERY 47 FOLLOW UP ON 47 proximal humeral fractures 47 polysomnographic 47 Neuropsychiatric Inventory NPI 47 Brain Metastases 47 RESPOND TO 47 polyarticular 47 DAS# CRP 47 urodynamic 47 Hospitalized Patients 47 nonoperative 47 aged ≥ 47 TURBT 47 total knee arthroplasty 47 coronary angiography 47 RE MODEL 47 Endometrial 47 Cardiotoxicity 47 BPS IC 47 Cohort 47 transcriptomic 47 serologically 47 acetabular fractures 47 Rating Scale BPRS 47 Predictors 47 Charlson Comorbidity Index 47 primary patency 47 FOR CHANGE 46 BEXXAR Therapeutic Regimen 46 Aortic Valve 46 Pharmacodynamics 46 Systolic Hypertension 46 Long Term Efficacy 46 Multivariate logistic regression 46 interobserver reliability 46 REMINDER ORLive Presents 46 Sentinel Lymph Node Biopsy 46 TOP SEEDS 46 CONCISE 46 chest radiography 46 Sexual Satisfaction 46 hypercholesterolemic 46 Postmenopausal Hormone Therapy 46 HBeAg 46 DSM IV SCID 46 Pearson correlation coefficients 46 cardiopulmonary bypass CPB 46 pT3 46 EXAMPLES OF 46 hip arthroplasty 46 opioid dependent 46 dichotomized 46 nondemented 46 plasma pharmacokinetics 46 End Results SEER 46 papillary thyroid carcinoma 46 Mammographic 46 CONCLUSION 46 parathyroidectomy 46 Vertebral Fractures 46 SPINE 46 proton MR spectroscopy 46 mg administered orally 46 ultrasonography 46 XIENCE V PROMUS Stent 46 placebo controlled studies 46 HCV RESPOND 2 46 Multicentre 46 CUTTING THE 46 computed tomographic scans 46 HABITS 46 Study ARIC 46 pharmacokinetics PK 46 USAGE 46 Prevent Stroke 46 BACK PAIN 46 PATENTS 46 Malignancy 46 Severity MSCS score 46 INSPECT 46 SURVIVE 46 intra articular injection 46 ACCLAIM 46 univariate analyzes 46 Atherosclerotic 46 DIFFERENCES 46 Regression analyzes 46 EINSTEIN DVT 46 Pharmacokinetic 46 Prostate Biopsy 46 venous thromboembolic disease 46 Prospective Cohort Study 46 Hemodynamic 46 Distress Scale 46 COMIN 46 SUGGEST THAT 46 DEGREE OF 46 % CI #.#-#.# [007] 46 DIVERSIFICATION 46 TOTALLY DIFFERENT 46 Neuroprotective Effects 46 PILOT PROGRAM 46 events SAEs 46 mITT 46 multicenter 46 STEP BD 46 NSQIP 46 PANSS 46 cluster randomized controlled 46 QRS duration 46 RADICALS 46 urodynamic studies 46 Coronary Arteries 46 Phenotypes 46 GASTRIC 46 mITT population 46 convergent validity 46 REYATAZ ritonavir 46 hip resurfacing arthroplasty 46 platelet dysfunction 46 Drug Eluting Stents 46 ventricular myocardium 46 radical prostatectomy RP 46 THE DESTRUCTION OF 46 Intracerebral 46 CLEARER 46 Treatment Resistant 46 HAND TO 46 Postmenopausal 46 Liver Fibrosis 46 #:#-# [029] 46 bivariate 46 randomized 46 USE YOUR 46 atazanavir ritonavir 46 interquartile range 46 Pharmacokinetic Study 46 FUNCTIONAL 46 Visual Analog Scale 46 intravesical 46 PERV 46 radiographic evaluation 46 morphometry 46 qRT PCR 46 tumor necrosis 46 ABSTRACT 46 Cardiopulmonary Bypass 46 flutamide 46 Knee Osteoarthritis 46 ENTITY 46 FAKED 46 ROAD MAP 46 BR.# 46 Phase III randomized 46 Cardiovascular Risk Factors 46 Remission Maintenance 46 Kidney Transplantation 46 transcriptional profiling 46 adjunctive placebo 46 de novo AML 46 vesicoureteral reflux 46 laparoscopic radical nephrectomy 46 HADS 46 ARTICLES 46 Immunogenicity 46 placebo controlled dose escalation 46 HORIZONS AMI trial 46 distal femur 46 dyssynchrony 46 Data Suggest 46 pulmonary metastases 46 STRESS AND 46 OUTCOMES 46 multiple linear regression 46 ASSESSING 46 Liver Tumors 46 Contraceptive Use 46 postmenopausal osteoporotic women 46 electrophysiologic 46 PROWESS 46 hemodialysis patients 46 EVEREST II 46 PSYCHOLOGICAL 46 ritonavir boosted 46 missense mutations 46 Multicenter AIDS 46 Ejection Fraction 46 INTERMACS 46 diffusion tensor 46 DUE FOR 46 Coronary Artery Calcium 46 Invasive Breast Cancer 46 variance ANOVA 46 Female Sexual Function 46 RE LY 46 esophagectomy 46 Antitumor Activity 46 Estrogen Receptor 46 Sonography 46 NAMCS 46 hip BMD 46 Nationwide Inpatient Sample 46 rs# [004] 46 Scale PANSS 46 lymphocytosis 46 YMRS 46 Replication NCS R 46 E1 CLO 46 Dose Response 46 T2 lesions 46 TRAINING FOR 46 muscle biopsies 46 Liraglutide Effect 46 preoperative evaluation 46 mCi 46 TAXUS IV 46 National Comorbidity Survey 46 Who Underwent 46 evaluable patients 46 subtrochanteric 46 perioperative mortality 46 CEUS 46 Percutaneous Tibial Nerve Stimulation 46 Sipuleucel T 46 LAMICTAL 46 label multicenter Phase 46 DRIVEN TO 46 endoscopic ultrasonography 46 gene expression profiles 46 lumbar interbody fusion 46 Improve Outcomes 46 ALTERED 46 Autologous Stem Cell Transplantation

Back to home page